Stock Analysis
- China
- /
- Medical Equipment
- /
- SHSE:688606
Hangzhou Alltest Biotech First Quarter 2024 Earnings: EPS: CN¥0.56 (vs CN¥0.51 in 1Q 2023)
Hangzhou Alltest Biotech (SHSE:688606) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥199.9m (down 15% from 1Q 2023).
- Net income: CN¥44.8m (up 11% from 1Q 2023).
- Profit margin: 22% (up from 17% in 1Q 2023).
- EPS: CN¥0.56 (up from CN¥0.51 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hangzhou Alltest Biotech shares are up 1.4% from a week ago.
Risk Analysis
It is worth noting though that we have found 3 warning signs for Hangzhou Alltest Biotech that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether Hangzhou Alltest Biotech is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688606
Hangzhou Alltest Biotech
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally.
Excellent balance sheet with acceptable track record.